2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Director Rodney A. Ferguson resigned from Launch One Acquisition Corp.'s board and its audit and compensation committees, effective immediately. The resignation leaves the audit committee with two members and the board without a majority of independent directors, so the company is out of compliance with two Nasdaq listing rules. The company says it intends to use Nasdaq cure periods and to appoint a new independent director, but no replacement had been named as of the report date.
Ferguson notified the company of his resignation on November 4, 2026, and said it was not due to any disagreement with the company.
The audit committee now has two members, Mr. Atwood and Mr. Rogers, below Nasdaq's three-member requirement; Nasdaq notified the company of this on December 6, 2026, a date later than the report's November 9, 2026 filing date.
Nasdaq notified the company on November 6, 2026 that the board no longer has a majority of independent directors.
No replacement director has been appointed, and the filing gives no assurance on timing.
Larimar Therapeutics said it completed its rolling Biologics License Application with the FDA, seeking accelerated approval of nomlabofusp for Friedreich's ataxia. The company also disclosed a preliminary, unaudited $128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, with its quarter-end close not yet complete, so shareholders should note that figure could change.
Rolling BLA submission to the FDA completed; the company seeks accelerated approval based on skin frataxin as a potential novel surrogate endpoint.
Preliminary cash, cash equivalents and marketable securities of approximately $128.7 million as of September 30, 2026, subject to change after financial statement closing procedures.
The updated corporate deck projects cash runway into late Q2 2027 and lists BLA acceptance for early 2027 and U.S. approval for mid-2027 as estimated timing.
Aldeyra asked the FDA's Division of Ophthalmology to request that review of the ADX-2191 IND for primary vitreoretinal lymphoma move to the Division of Hematologic Malignancies 2, and it withdrew the Special Protocol Assessment for the planned trial. The company said the regulatory path is now uncertain and may be significantly delayed, and that the planned trial will need to be redesigned, which could raise costs and shorten its cash runway.
Aldeyra requested a review jurisdiction transfer to the FDA's Division of Hematologic Malignancies 2 (DHM2), announced November 9, 2026
The company withdrew the SPA protocol for ADX-2191 in PVRL, which the Division of Ophthalmology had previously agreed to
Aldeyra does not expect to start the planned trial while the request is pending; the FDA may deny the request or transfer the IND to another division
The filing warns of higher costs, a shorter cash runway and possible need for earlier capital raising
TMC USA, a subsidiary of TMC the metals Co Inc., received a letter from NOAA stating it expects to notify TMC USA of its final determination on certification of its consolidated application for an exploration license and commercial recovery permit by mid-December 2026. The filing notes the timing is an estimate, DSHMRA sets no mandatory deadline, and certification is an intermediate step that is not an approval or issuance of a license or permit.
NOAA letter received by TMC USA on November 3, 2026
NOAA expects to notify TMC USA of its final determination on certification by mid-December 2026
Application covers an exploration license and a commercial recovery permit under DSHMRA
Filing states certification does not constitute approval or issuance of a license or permit
Vistagen reported constructive FDA feedback from a Type C meeting on registrational paths for its lead product candidate, fasedienol, in social anxiety disorder. The company plans to use interim assessments, submit a revised protocol, and focus development on the general SAD population rather than acute treatment alone.
FDA gave constructive feedback on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study.
Vistagen plans to add interim assessments using eDiaries and qualitative patient surveys and to submit a revised protocol to the FDA.
The company plans to pursue fasedienol for overall, not only acute, treatment of SAD, and cited the FDA's recognition of its reported safety profile.
The filing contains no financial results, and the company states that future FDA feedback may not lead to a successful registrational pathway.
Future Vision II Acquisition Corp. (FVN) received written notice on November 5, 2026, from Nasdaq confirming it has regained compliance with the minimum public holders requirement for continued listing on the Nasdaq Capital Market. Nasdaq said the matter is now closed, so the company is no longer under this listing deficiency.
Notice received November 5, 2026 from Nasdaq's Listing Qualifications Department
Compliance regained with minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3)
Nasdaq stated the matter is closed; the 8-K was signed by CEO and Director Danhua Xu on November 9, 2026
Netcapital received a Nasdaq letter on November 5, 2026 granting it an exception to regain compliance with the periodic filing rule, after it missed deadlines for its annual report for the fiscal year ended April 30, 2026 and its quarterly report for the quarter ended July 31, 2026. The company must file both reports by February 9, 2027, or Nasdaq will issue a delisting notice, which the company could appeal to a Nasdaq Hearings Panel. The letter has no immediate effect on trading, but the company says there can be no assurance it will meet the deadline.
Nasdaq Staff letter dated November 5, 2026 grants an exception under Listing Rule 5250(c)(1).
Delinquent Form 10-K (fiscal year ended April 30, 2026) and Form 10-Q (quarter ended July 31, 2026) must be filed on or before February 9, 2027.
If the deadline is missed, Nasdaq will provide written notice of delisting, and the company may appeal to a Nasdaq Hearings Panel.
The letter has no immediate effect on the listing or trading of the common stock.
Novocure said it received a Not Approvable Letter from the U.S. Food and Drug Administration for its Premarket Approval application for Optune Mya, which treats adult patients with brain metastases from non-small cell lung cancer after stereotactic radiation. The FDA said uncertainty about the degree of clinical benefit prevented approval, and the company said it has no assurance that further discussions or submissions will lead to approval.
The FDA's Not Approvable Letter cites uncertainty around the degree of clinical benefit provided by Optune Mya.
The FDA did not raise concerns about the device's safety profile.
Novocure plans to meet with the FDA to see whether any options could support approval without additional clinical studies.
The filing gives no timeline for those discussions and no assurance of approval.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.